文献速递肺外科

EGFR-TKI诱导后手术治疗N2肺腺癌的可行性

Feasibility of Surgical Resection After Induction Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapy for N2 Lung Adenocarcinomas.
PubMed 文献 · Ann Thorac Surg · 2020-06-20

该II期临床试验评估了厄洛替尼诱导后手术治疗IIIA-N2期EGFR突变肺腺癌的安全性和可行性,并与同期新辅助化疗组对比。结果显示两组围手术期结果和1年、3年生存率无显著差异,诱导有效者胸腔镜切除率更高,结论认为厄洛替尼诱导后肺切除安全可行。

要点

  • 厄洛替尼诱导后手术并发症和住院时间与化疗组相当
  • 诱导有效者胸腔镜切除率92.3%,高于无效者68.8%
  • 超过肺叶切除及不完全切除仅见于诱导后稳定者

核心结论

  • IIIA-N2期EGFR突变肺腺癌患者接受厄洛替尼诱导治疗后行肺切除是安全可行的。
  • 对有效诱导治疗有反应的患者可能获得更好的手术和肿瘤学结果。

研究设计与样本

  • 对照组为同期15例接受新辅助化疗的患者,比较围手术期结果和生存。

主要发现

  • 厄洛替尼组诱导前血清癌胚抗原水平显著高于化疗组,诱导后降至相似水平。
  • 两组手术时间、出血量、切除范围、完全切除率、术后引流、并发症率和住院时间均相当。
  • 厄洛替尼组胸腔镜切除率78.6%,化疗组80.0%(P = .924);诱导有效者92.3% vs 无效者68.8%(P = .119)。
  • 两组1年和3年总生存或无病生存均无显著差异。

关键数值与推荐

  • 胸腔镜切除率:厄洛替尼组78.6%,化疗组80.0%(P = .924)。
  • 诱导有效者胸腔镜切除率92.3%,无效者68.8%(P = .119)。

临床怎么用

  • 对于IIIA-N2期EGFR突变肺腺癌,可考虑厄洛替尼诱导后手术,围手术期风险与化疗相当。
  • 诱导治疗反应好者更可能完成胸腔镜切除,应重视疗效评估。

局限性

  • 原文未报告长期生存随访的具体时限和更多细节。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Prognosis of patients with stage IIIA-N2 lung adenocarcinoma is still not optimistic. The aim of this study was to evaluate safety, feasibility, and outcomes of surgery after induction epidermal growth factor receptor-tyrosine kinase inhibitor therapy in a clinical trial setting. METHODS: Fourteen patients with IIIA-N2 lung adenocarcinoma and epidermal growth factor receptor mutation received erlotinib induction followed by surgery in a phase II clinical trial. Perioperative outcomes and survival results were compared with a control group of 15 patients receiving neoadjuvant chemotherapy during the same time period. RESULTS: Thirteen patients showed partial response to induction, whereas 16 patients remained stable. Serum carcinoembryonic antigen level in the erlotinib group was significantly higher than in the chemotherapy group before treatment but was reduced to similar levels after induction. Operation time, blood loss, resection extents, complete resection rates, postoperative drainage, complication rates, and length of hospital stay were all comparable between the 2 groups. Thoracoscopic resection was accomplished in 78.6% of patients in the erlotinib group and 80.0% of patients in the chemotherapy group (P = .924) but was higher in patients who responded to induction than those who did not (92.3% vs 68.8%, P = .119). A resection extent greater than lobectomy and incomplete resections were only seen in stable disease after induction. No significant difference was detected in 1-year and 3-year overall or disease-free survivals between the 2 groups. CONCLUSIONS: Pulmonary resection is safe and feasible after induction treatment with erlotinib for stage IIIA-N2 lung adenocarcinomas. Better surgical and oncologic outcomes may be expected in patients who respond to effective induction therapies.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Zhao W, Chen T, Ji C, et al. Feasibility of Surgical Resection After Induction Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapy for N2 Lung Adenocarcinomas. Ann Thorac Surg. 2020. PMID: 32569671. doi:10.1016/j.athoracsur.2020.04.133

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。